Metabolic Balance Study of FE203799 in Patients With SBS With Intestinal Insufficiency

Authors
Category Primary study
Registry of Trialsclinicaltrials.gov
Year 2018
This is a repeated dose, open label trial investigating safety, efficacy, PD and PK of FE 203799 in 8 patients with SBS. The patients will receive a subcutaneous (SC) dose of 5 mg FE 203799 once weekly for 4 consecutive weeks, and efficacy parameters and PK will be assessed after the fourth dose. Safety follow up assessments will be performed 4-6 weeks after the last dose.
Epistemonikos ID: 7b86e191a1182a76a626137c9a62710909120a7b
First added on: May 21, 2024